封面
市场调查报告书
商品编码
1528025

全球生长因子市场(血液和组织)

Growth Factors (Blood and Tissue)

出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 223 Pages | 商品交期: 最快1-2个工作天内

价格

本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

到 2030 年,全球生长因子(血液和组织)市场将达到 1,015 亿美元

2023 年全球生长因子(血液和组织)市场估计为 584 亿美元,预计到 2030 年将达到 1015 亿美元,在 2023-2030 年分析期间复合年增长率为 8.2%。干扰素是本报告分析的细分市场之一,预计复合年增长率为 9.9%,到分析期结束时将达到 782 亿美元。在分析期间,菌落刺激因子产业的复合年增长率预计为-1.5%。

美国市场预计153亿美元,中国预计复合年增长率12.7%

到 2023 年,美国生长因子(血液和组织)市场预计将达到 153 亿美元。中国作为世界第二大经济体,预计2030年市场规模将达262亿美元,2023-2030年分析期间复合年增长率为12.7%。其他值得注意的区域市场包括日本和加拿大,在分析期间预计复合年增长率分别为 4.0% 和 7.4%。在欧洲,德国预计复合年增长率为 5.0%。

全球生长因子(血液和组织)市场—主要趋势和驱动因素总结

什么是生长因子?

生长因子是天然存在的蛋白质或激素,在调节各种细胞过程(包括细胞增殖、分化和组织修復)中发挥至关重要的作用。这些生物分子对于人体对损伤和疾病的反应非常重要,可促进受损组织的修復和再生。表皮生长因子(EGF)、纤维母细胞生长因子(FGF)和血管内皮生长因子(VEGF)等生长因子的治疗潜力已被广泛研究。在临床环境中,生长因子用于促进创伤治疗、支持移植组织的生长并改善再生医学手术的结果。这些生长因子能够刺激人体的内源性修復机制,这使得它们在治疗从慢性伤口和烧烫伤到心血管疾病和整形外科损伤等多种疾病方面具有重要价值。

科技创新如何促进生长因子在医学上的应用?

技术进步极大地促进了生长因子在医学中的应用,扩大了其治疗潜力和有效性。生物技术和基因工程的最新创新使得重组生长因子得以大规模生产,使其更容易获得且更具成本效益。此外,奈米颗粒和水凝胶等先进递送系统的开发改善了生长因子向损伤部位的标靶递送和持续释放,从而提高了治疗效果。组织工程和组织工程也受益于这些进步,生长因子被纳入支架和生物材料中以促进组织再生和修復。这些技术进步不仅提高了生长因子的有效性,也为复杂的医疗程序和治疗应用开闢了新的可能性。

为何各医疗领域对生长因子的需求快速成长?

随着人们对生长因子治疗效果的认识不断提高,各个医学领域对生长因子的需求正在迅速增加。在皮肤病学中,生长因子用于美容手术,以促进皮肤年轻化并减少老化征兆。在整形外科中,它对于促进骨折和软组织损伤的癒合具有重要作用。生长因子也用于心血管领域,以促进血管生成并改善缺血性疾病患者的血流。生长因子在再生医学领域也至关重要,它们被用来培养干细胞和发育用于移植的活组织。生长因子在这些不同医疗领域的不断扩大应用强调了它们在现代医疗保健中的重要性,并促使人们不断进行研究和开发以充分发挥其潜力。

推动生长因子市场成长的因素有哪些?

成长因素市场的成长是由多种因素所推动的。生物技术和基因工程的技术进步使得重组生长因子的生产更加高效且更具成本效益,从而提高了其可用性。需要组织修復和再生的慢性疾病和病症(例如糖尿病和心血管疾病)的日益流行,正在推动对生长因子的需求。此外,越来越多地采用严重依赖生长因子的再生医学和组织工程方法也推动了市场成长。利用生长因子促进皮肤再生和创伤治疗的美容和皮肤科手术的兴起进一步扩大了市场。此外,增强生长因子功效和标靶作用的创新药物输送系统的开拓正在吸引大量投资并推动市场扩张。政府资助和先进治疗应用的支持性法律规范在推动生长因子市场的成长方面也发挥着重要作用。

受访企业范例(101家知名企业)

  • Amgen, Inc.
  • Bayer HealthCare Pharmaceuticals, Inc.
  • Biocon Ltd.
  • Biogen, Inc.
  • Biopharm GmbH
  • Bolder BioTechnology, Inc.
  • Chugai Pharmaceutical Co. Ltd.
  • F. Hoffmann-La Roche AG
  • FibroGen, Inc.
  • Genentech, Inc.
  • Janssen Biotech, Inc.
  • Johnson & Johnson
  • Lonza Group
  • Merck Serono
  • PeproTech, Inc.
  • Reliance GeneMedix Plc
  • Sangamo Therapeutics, Inc.
  • Sanofi
  • Scil Proteins GmbH
  • Teva Pharmaceutical Industries Ltd.
  • Wockhardt Ltd.

目录

第一章调查方法

第 2 章执行摘要

  • 市场概况
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 澳洲
  • 印度
  • 韩国
  • 其他亚太地区
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 伊朗
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他中东地区
  • 非洲

第四章 比赛

简介目录
Product Code: MCP-1217

Global Growth Factors (Blood and Tissue) Market to Reach US$101.5 Billion by 2030

The global market for Growth Factors (Blood and Tissue) estimated at US$58.4 Billion in the year 2023, is expected to reach US$101.5 Billion by 2030, growing at a CAGR of 8.2% over the analysis period 2023-2030. Interferons, one of the segments analyzed in the report, is expected to record a 9.9% CAGR and reach US$78.2 Billion by the end of the analysis period. Growth in the Colony Stimulating Factors segment is estimated at -1.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$15.3 Billion While China is Forecast to Grow at 12.7% CAGR

The Growth Factors (Blood and Tissue) market in the U.S. is estimated at US$15.3 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$26.2 Billion by the year 2030 trailing a CAGR of 12.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.0% and 7.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Global Growth Factors (Blood and Tissue) Market - Key Trends and Drivers Summarized

What Are Growth Factors and Why Are They Crucial for Medical Advancements?

Growth factors are naturally occurring proteins or hormones that play a pivotal role in regulating various cellular processes, including cell proliferation, differentiation, and tissue repair. These biological molecules are critical in the body's response to injury and disease, facilitating the repair and regeneration of damaged tissues. Growth factors such as epidermal growth factor (EGF), fibroblast growth factor (FGF), and vascular endothelial growth factor (VEGF) are extensively studied for their therapeutic potential. In clinical settings, growth factors are utilized to enhance wound healing, support the growth of grafted tissues, and improve the outcomes of regenerative medicine procedures. The ability of these factors to stimulate the body's intrinsic repair mechanisms makes them invaluable in treating a wide range of medical conditions, from chronic wounds and burns to cardiovascular diseases and orthopedic injuries.

How Are Technological Innovations Enhancing the Use of Growth Factors in Medicine?

Technological advancements are significantly boosting the application of growth factors in medicine, expanding their therapeutic potential and efficacy. Recent innovations in biotechnology and genetic engineering have enabled the large-scale production of recombinant growth factors, making them more accessible and cost-effective. Additionally, the development of advanced delivery systems, such as nanoparticles and hydrogels, has improved the targeted delivery and sustained release of growth factors at the injury site, enhancing their therapeutic impact. Tissue engineering and regenerative medicine have also benefited from these advancements, with growth factors being incorporated into scaffolds and biomaterials to promote tissue regeneration and repair. These technological strides not only enhance the effectiveness of growth factors but also open up new possibilities for their application in complex medical procedures and treatments.

Why Is There a Surge in Demand for Growth Factors in Various Medical Fields?

The increasing recognition of the therapeutic benefits of growth factors has led to a surge in their demand across various medical fields. In dermatology, growth factors are used in cosmetic procedures to stimulate skin rejuvenation and reduce signs of aging. In orthopedics, they play a crucial role in accelerating the healing of bone fractures and soft tissue injuries. The cardiovascular field also leverages growth factors to promote angiogenesis and improve blood flow in patients with ischemic conditions. Moreover, growth factors are integral to the field of regenerative medicine, where they are used to cultivate stem cells and develop bioengineered tissues for transplantation. The expanding application of growth factors in these diverse medical domains underscores their importance in modern healthcare and drives continuous research and development efforts to explore their full potential.

What Factors Are Driving the Growth in the Growth Factors Market?

The growth in the growth factors market is driven by several factors. Technological advancements in biotechnology and genetic engineering are making the production of recombinant growth factors more efficient and cost-effective, thereby increasing their availability. The rising prevalence of chronic diseases and conditions that require tissue repair and regeneration, such as diabetes and cardiovascular diseases, is spurring demand for growth factors. Additionally, the increasing adoption of regenerative medicine and tissue engineering approaches, which rely heavily on growth factors, is propelling market growth. The growing number of cosmetic and dermatological procedures that utilize growth factors for skin rejuvenation and wound healing further expands the market. Moreover, the development of innovative drug delivery systems that enhance the efficacy and targeted action of growth factors is attracting significant investments and fostering market expansion. Government funding and supportive regulatory frameworks for advanced therapeutic applications also play a crucial role in driving the growth of the growth factors market.

Select Competitors (Total 101 Featured) -

  • Amgen, Inc.
  • Bayer HealthCare Pharmaceuticals, Inc.
  • Biocon Ltd.
  • Biogen, Inc.
  • Biopharm GmbH
  • Bolder BioTechnology, Inc.
  • Chugai Pharmaceutical Co. Ltd.
  • F. Hoffmann-La Roche AG
  • FibroGen, Inc.
  • Genentech, Inc.
  • Janssen Biotech, Inc.
  • Johnson & Johnson
  • Lonza Group
  • Merck Serono
  • PeproTech, Inc.
  • Reliance GeneMedix Plc
  • Sangamo Therapeutics, Inc.
  • Sanofi
  • Scil Proteins GmbH
  • Teva Pharmaceutical Industries Ltd.
  • Wockhardt Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Growth Factors (Blood and Tissue) - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Prevalence of Chronic Diseases Spurs Demand for Growth Factors
    • Rise in Regenerative Medicine Expands Addressable Market Opportunity
    • Innovations in Drug Delivery Systems Strengthen Business Case for Growth Factors
    • Advancements in Biotechnology Propel Growth in Growth Factors Market
    • Growing Adoption of Tissue Engineering Generates Demand for Growth Factors
    • Integration of Growth Factors in Orthopedic Treatments Propels Market Expansion
    • Increasing Application of Growth Factors in Cardiovascular Therapies
    • Advances in Genetic Engineering Accelerate Demand for Recombinant Growth Factors
    • Expansion of Stem Cell Research Throws the Spotlight on Growth Factors
    • Technological Innovations in Biomaterials Propel Growth in the Use of Growth Factors
    • Rising Demand for Growth Factors in Wound Healing and Burn Treatment Expands Market Scope
    • Impact of Aging Population on Demand for Growth Factors in Age-Related Therapies
    • Personalized Medicine and Its Influence on Growth Factors Market Trends
    • Here's the Story on Growth Factors in Neurological Repair and Regeneration
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Growth Factors (Blood and Tissue) Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Growth Factors (Blood and Tissue) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Growth Factors (Blood and Tissue) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Interferons by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Interferons by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Interferons by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Colony Stimulating Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Colony Stimulating Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Colony Stimulating Factors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Erythropoietins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Erythropoietins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Erythropoietins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Interleukins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Interleukins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Interleukins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Growth Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Growth Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • JAPAN
    • Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 26: Japan Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Japan Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: Japan 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • CHINA
    • Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 29: China Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: China Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: China 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • EUROPE
    • Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Growth Factors (Blood and Tissue) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Europe 16-Year Perspective for Growth Factors (Blood and Tissue) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 35: Europe Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Europe Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Europe 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • FRANCE
    • Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 38: France Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: France Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: France 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • GERMANY
    • Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 41: Germany Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Germany Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Germany 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 44: Italy Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Italy Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Italy 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 47: UK Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: UK Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: UK 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 50: Spain Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Spain Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Spain 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 53: Russia Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Russia Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Russia 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Rest of Europe Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Rest of Europe 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 60: Asia-Pacific Historic Review for Growth Factors (Blood and Tissue) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Asia-Pacific 16-Year Perspective for Growth Factors (Blood and Tissue) by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Asia-Pacific Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Asia-Pacific 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 65: Australia Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Australia Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Australia 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • INDIA
    • Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 68: India Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: India Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: India 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 71: South Korea Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: South Korea Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: South Korea 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 74: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Rest of Asia-Pacific Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Rest of Asia-Pacific 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 77: Latin America Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 78: Latin America Historic Review for Growth Factors (Blood and Tissue) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Latin America 16-Year Perspective for Growth Factors (Blood and Tissue) by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 80: Latin America Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Latin America Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Latin America 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 83: Argentina Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Argentina Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Argentina 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 86: Brazil Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Brazil Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Brazil 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 89: Mexico Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Mexico Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Mexico 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 92: Rest of Latin America Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Latin America Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Latin America 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 95: Middle East Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 96: Middle East Historic Review for Growth Factors (Blood and Tissue) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Middle East 16-Year Perspective for Growth Factors (Blood and Tissue) by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 98: Middle East Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Middle East Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Middle East 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 101: Iran Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Iran Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Iran 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 104: Israel Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Israel Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Israel 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 107: Saudi Arabia Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Saudi Arabia Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Saudi Arabia 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 110: UAE Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: UAE Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: UAE 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 113: Rest of Middle East Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Rest of Middle East Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Rest of Middle East 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • AFRICA
    • Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 116: Africa Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Africa Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Africa 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030

IV. COMPETITION